On Monday, January 31, Japanese pharmaceutical company Kowa announced that they have “confirmed that ivermectin has the same antiviral effect against the Omicron strain” that it does against other known strains of SARS-CoV-2, including Alpha, Beta, Gamma, and Delta.
Kowa has been working with Tokyo medical school Kitasato University, after a request from Nobel Prize winner Satoshi Omura, to conduct clinical trials of ivermectin as a treatment for SARS-CoV-2 infection.
According to Kowa’s latest press release, the company’s clinical trials to confirm the efficacy and safety of ivermectin as a treatment for SARS-CoV-2 infection are ongoing.
According to the study listing at ClinicalTrials.gov, a dose of “0.3-0.4 mg/kg orally administered once daily for 3 days will be evaluated in patients with mild COVID-19 using a randomized, double-blind, parallel-group comparative method with placebo as a control.”
The World Council for Health continues to recommend the use of ivermectin in our Early Covid-19 Treatment Guide and Spike Protein Detox Guide.
